China Life Healthcare Fund and Venus Medtech have taken part in a round for the heart valve treatment developer sized in the hundreds of millions of dollars.

The Takeda and Access Industries-backed oncology therapeutics developer is targeting an offering on the Nasdaq Global Market having previously raised $190m.

GV was among the investors in a series A round led by Andreessen Horowitz closed three years after the gene therapy developer's launch.

The Atrium Health-backed clinical trial software provider increased its overall funding to over $88m in a round led by Insight Partners.

Genetic sequencing platform developer TwinStrand has secured $50m in a series B round led by Section 32, while Alexandria Venture Investments invested for a third time.

Evotec has partnered Bristol-Myers Squibb to launch another Bridge programme, this time focusing on the universities of Birmingham, Dundee, Edinburgh and Nottingham.

Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.

Evotec has partnered Bristol-Myers Squibb to launch another Bridge programme, this time focusing on the universities of Birmingham, Dundee, Edinburgh and Nottingham.

UW spinout TwinStrand has completed a $50m series B round led by Section 32, while Alexandria Venture Investments invested a third time.

Opioid addiction care provider Groups Recover Together and healthcare management platform developer Vim each raised $60m, with Optum Ventures backing both rounds.